Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc. announced the completion of its acquisition of Kashiv BioSciences, LLC for a preliminary purchase price of $1.3 billion. The acquisition, which closed on August 10, 2026, involved cash, equity, and significant contingent consideration. The company also reported its financial results for the nine months ended September 30, 2026, with net revenue increasing by 8.0% to $2.38 billion and net income attributable to Amneal increasing to $98.2 million. The balance sheet reflects a substantial increase in assets and liabilities due to the Kashiv acquisition.

Amneal Pharmaceuticals announced its third quarter 2026 financial results, reporting a 10% increase in net revenue to $863 million and a 30% rise in Adjusted EBITDA to $207 million. The company also saw a 53% increase in Adjusted Diluted EPS to $0.26. Despite a GAAP net loss of $22 million, driven by acquisition and integration costs, Amneal is increasing its full-year 2026 guidance for net revenue, Adjusted EBITDA, and Adjusted Diluted EPS. The company highlighted strong performance across its segments, successful integration of Kashiv, and upcoming product launches.

Amneal Pharmaceuticals, Inc. announced the completion of its acquisition of Kashiv BioSciences, LLC on August 10, 2026. The transaction involved a cash payment of $375 million and the issuance of 28.9 million shares of Amneal's Class A common stock. Additionally, Kashiv sellers are eligible for up to $350 million in contingent regulatory milestone payments and 12 years of contingent royalty payments. To help finance the acquisition, Amneal LLC secured a $350 million Incremental Term Loan. This strategic acquisition aims to establish Amneal as a fully integrated global biosimilar leader, extending its growth profile into the next decade.

Amneal Pharmaceuticals reported strong second-quarter 2026 results with net revenue increasing to $796.2 million and net income attributable to the company rising to $57.7 million. The company also announced several strategic agreements, including an exclusive distribution deal for generic mirabegron with MSN Laboratories, a license and supply agreement with Adalvo for two generic tirzepatide products, and a supply agreement with mAbxience for denosumab biosimilars. Additionally, an update to the Pfizer collaboration resulted in a $6.9 million gain.

Amneal Pharmaceuticals' subsidiary, Amneal Pharmaceuticals LLC, entered into a Repricing Amendment to its Term Loan Credit Agreement. This amendment reduces the applicable interest rate margin on its $2.084 billion term loans by 50 basis points, resulting in estimated annualized cash interest expense savings of approximately $12 million. The new interest rates are 1.50% (base rate) and 2.50% (SOFR), with the maturity date remaining August 1, 2032.

Amneal Pharmaceuticals reported strong second-quarter 2026 results with net revenue of $796 million, a 10% increase year-over-year, and GAAP net income of $58 million, up 157%. Diluted EPS reached $0.18, while adjusted diluted EPS was $0.30. The company also raised its full-year 2026 guidance for net revenue, adjusted EBITDA, and adjusted diluted EPS for the second time this year, reflecting confidence in its diversified portfolio and growth drivers. Additionally, a debt repricing in July is expected to reduce annual interest costs by $12 million.

Amneal Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for additional strengths and vial presentations of iohexol injection. This includes 350 mg iodine/mL in 50 mL, 75 mL, and 100 mL vials, and 300 mg iodine/mL in a 50 mL vial. The company plans to launch these products in the third quarter of 2026, positioning its iohexol portfolio to address the majority of the U.S. market demand for the radiographic contrast agent, which had approximately $706 million in U.S. annual sales.

Amneal Pharmaceuticals, Inc. announced it will report its second quarter 2026 financial results on Thursday, July 30, 2026, before the market opens. Following the release, the company will host an audio webcast at 8:30 a.m. ET to discuss the results. Investors can access the financial results and live webcast through the Investor Relations section of Amneal's website.

Amneal Pharmaceuticals and Zambon announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization for Hopledo® in Europe. Hopledo®, known as CREXONT® in the U.S., is a novel oral formulation for Parkinson's disease patients experiencing moderate to severe motor fluctuations. This recommendation, based on positive Phase 3 trial data, paves the way for a new treatment option for over one million Parkinson's patients in the EU, with a phased launch expected to begin in October 2026.

Amneal Pharmaceuticals announced positive interim results from its Phase 4 ELEVATE-PD study for CREXONT (carbidopa and levodopa) extended-release capsules. The study, involving 214 patients, demonstrated clinically meaningful benefits, including substantial increases in "Good On" time, reductions in "Off" time, and improved motor function, regardless of prior treatment. Patients switching from RYTARY® nearly doubled their continuous "Good On" intervals. The safety profile was consistent with prior therapy, and the company recently received an FDA labeling update for an additional administration option.